MEGZURPAZ Trademark

Trademark Overview


On Thursday, May 13, 2021, a trademark application was filed for MEGZURPAZ with the United States Patent and Trademark Office. The USPTO has given the MEGZURPAZ trademark a serial number of 90710106. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, June 18, 2024. This trademark is owned by Celgene Corporation. The MEGZURPAZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy
megzurpaz

General Information


Serial Number90710106
Word MarkMEGZURPAZ
Filing DateThursday, May 13, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, June 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 8, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Tuesday, January 25, 2022NON-FINAL ACTION WRITTEN
Monday, May 17, 2021NEW APPLICATION ENTERED
Thursday, August 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 20, 2022ASSIGNED TO EXAMINER
Tuesday, January 25, 2022NON-FINAL ACTION E-MAILED
Tuesday, January 25, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 8, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, August 8, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, August 9, 2022TEAS PETITION TO REVIVE RECEIVED
Tuesday, August 9, 2022PETITION TO REVIVE-GRANTED
Tuesday, August 9, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 9, 2022NOTICE OF REVIVAL - E-MAILED
Monday, September 12, 2022ASSIGNED TO LIE
Tuesday, September 13, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 13, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, October 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 19, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 8, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 8, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 3, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, June 28, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, June 28, 2023SOU EXTENSION 1 FILED
Wednesday, June 28, 2023SOU EXTENSION 1 GRANTED
Friday, June 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 2, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 2, 2024SOU EXTENSION 2 FILED
Tuesday, January 2, 2024SOU EXTENSION 2 GRANTED
Tuesday, June 18, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024SOU EXTENSION 3 FILED
Tuesday, June 18, 2024SOU EXTENSION 3 GRANTED
Thursday, January 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED